Adenosine vs Diltiazem for Treatment of SVT in the ED | NCT06993038

Studies
Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038

Sponsor

Anne E. Zepeski

Status

Recruiting

Last Update Posted

May 28, 2026Actual

Enrollment

20Estimated

Phase

Phase 4

Conditions

Supraventricular Tachycardia (SVT)

Interventions

adenosine
diltiazem

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2026

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Aug 1, 2025Actual

Primary Completion Date

Jul 2027Estimated

Completion Date

Dec 2027Estimated

First Submitted Date

Apr 3, 2025

First Submission Date that Met QC Criteria

May 19, 2025

First Posted Date

May 28, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

May 26, 2026

Last Update Posted Date

May 28, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Yes

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

FDAAA801 Violation

Not provided

Description Module

Brief Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 4

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

20Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Adenosine	Active Comparator		Drug: adenosine
Diltiazem	Active Comparator		Drug: diltiazem

Interventions

Name	Type	Description	Arm Group Labels	Other Names
adenosine	Drug	IV adenosine at standard doses for SVT (6 mg, 12 mg)	Adenosine

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Feasibility outcome	Patients with stable SVT are identified in the ED (Threshold >90%)	From enrollment to the end of ED encounter (up to 24 hours).
Feasibility outcome	Eligible participants who provide consent to participate (Threshold >50%)	From enrollment to the end of ED encounter (up to 24 hours).
Feasibility outcome	Participants who complete all study procedures (Threshold >80%)	From enrollment to the end of ED encounter (up to 24 hours).

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adult patients (18 years and older)
Diagnosis of acute, stable SVT in the emergency department

Exclusion Criteria:

Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
History of heart failure with reduce ejection fraction (HFrEF) (LVEF\

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

100 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Anne Zepeski, PharmD	Contact	(319) 356-2577		anne-zepeski@uiowa.edu

Overall Officials

Name	Affiliation	Role
Anne Zepeski, PharmD	University of Iowa	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
University of Iowa Health Care	Recruiting	Iowa City	Iowa	52242	United States

IPD Sharing Statement Module

Plan to Share IPD

Description

We have no plans to share individual participant data, pursuant to local IRB approval and policies.

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D013617	Tachycardia, Supraventricular

Ancestor Terms

ID	Term
D013610	Tachycardia
D001145	Arrhythmias, Cardiac
D006331	Heart Diseases
D002318	Cardiovascular Diseases

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D000241	Adenosine
D004110	Diltiazem

Ancestor Terms

ID	Term
D011684	Purine Nucleosides
D011687	Purines
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring

Browse Leaves

Not provided

Browse Branches

Not provided